Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10994683 | 0.85 | HPGD (0.49) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL9313156 | 0.84 | TDP1 (0.67) | TDP1ALOX15LMNAALDH1A1MEN1 | |
| SCHEMBL8474931 | 0.83 | PNMT (0.48) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL10998223 | 0.83 | HPGD (0.51) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL24235222 | 0.80 | HPGD (0.49) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL13934710 | 0.80 | ALDH1A1 (0.55) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL19832126 | 0.80 | ALDH1A1 (0.55) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL16571409 | 0.80 | ADRB2 (0.45) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL1642716 | 0.79 | HPGD (0.47) | TDP1ALOX15HPGDGRM5LMNA | |
| SCHEMBL25134499 | 0.79 | MAPK1 (0.54) | ALOX15HPGDGRM5LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0348737-B1 | HETEROARYLOXY-ACETIC ACID N-ISOPROPYL ANILIDES | BAYER AG (DE) | 1993-08-04 | — | — | EP | claimed |
| WO-2024118607-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CHDI FOUNDATION, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | disclosed |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2023055702-A1 | MAIN PROTEASE (M PRO) INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | WO | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-01-25 | — | — | US | disclosed |
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| US-7273881-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| WO-2003035057-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
| US-5817876-A | ONE POT; REACTING AN NITROARENE WITH A CARBONYL COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0491968-B1 | Process for the preparation of N-alkyl-fluoroanilines | BAYER AG (DE) | 1994-10-26 | — | — | EP | disclosed |
| EP-0355351-B1 | Process for the preparation of amines | BAYER AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0491968-A1 | Process for the preparation of N-alkyl-fluoroanilines | BAYER AG (DE) | 1992-07-01 | — | — | EP | disclosed |
| US-5011996-A | Process for the preparation of amines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-30 | — | — | US | disclosed |
| EP-0355351-A2 | Process for the preparation of amines | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229649-B2 | Methods for treating cryptosporidiosis using triazolopyridazines | CLPP, SI, SAMHD1 | TDP1 1472/4885ALOX15 1745/4885HPGD 1627/4885 |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | TDP1 1140/4885ALOX15 3/4885HPGD 28/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | TDP1 28/4885ALOX15 545/4885HPGD 1016/4885 |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | CCL11, MMP1, HDGF | TDP1 3745/4885ALOX15 423/4885HPGD 787/4885 |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | TDP1 1488/4885ALOX15 2456/4885HPGD 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.